Mutual of America Capital Management LLC Has $2.16 Million Holdings in Abiomed, Inc. (NASDAQ:ABMD)

Mutual of America Capital Management LLC raised its stake in shares of Abiomed, Inc. (NASDAQ:ABMDGet Rating) by 0.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 6,017 shares of the medical equipment provider’s stock after purchasing an additional 53 shares during the period. Mutual of America Capital Management LLC’s holdings in Abiomed were worth $2,161,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ABMD. Daiwa Securities Group Inc. lifted its holdings in shares of Abiomed by 6.7% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,688 shares of the medical equipment provider’s stock valued at $965,000 after purchasing an additional 168 shares in the last quarter. Knowledge Leaders Capital LLC lifted its stake in Abiomed by 10.8% during the 4th quarter. Knowledge Leaders Capital LLC now owns 1,768 shares of the medical equipment provider’s stock valued at $635,000 after acquiring an additional 172 shares in the last quarter. Pictet & Cie Europe SA boosted its holdings in Abiomed by 11.8% during the 4th quarter. Pictet & Cie Europe SA now owns 1,865 shares of the medical equipment provider’s stock worth $670,000 after acquiring an additional 197 shares during the last quarter. Banque Pictet & Cie SA grew its stake in shares of Abiomed by 517.1% in the 4th quarter. Banque Pictet & Cie SA now owns 30,859 shares of the medical equipment provider’s stock worth $11,084,000 after acquiring an additional 25,858 shares in the last quarter. Finally, Hartford Investment Management Co. raised its holdings in shares of Abiomed by 8.7% in the fourth quarter. Hartford Investment Management Co. now owns 4,611 shares of the medical equipment provider’s stock valued at $1,656,000 after purchasing an additional 369 shares during the last quarter. Institutional investors and hedge funds own 91.91% of the company’s stock.

A number of brokerages have issued reports on ABMD. Wolfe Research initiated coverage on shares of Abiomed in a research report on Tuesday, April 5th. They issued a “market perform” rating and a $330.00 price objective for the company. StockNews.com began coverage on Abiomed in a report on Thursday, March 31st. They issued a “hold” rating for the company. SVB Leerink dropped their price target on Abiomed from $345.00 to $325.00 and set a “market perform” rating on the stock in a report on Friday, February 4th. Finally, Morgan Stanley cut their price objective on Abiomed from $292.00 to $275.00 and set an “underweight” rating on the stock in a research report on Friday, February 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $341.80.

In related news, CFO Todd A. Trapp sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $333.00, for a total value of $333,000.00. Following the completion of the transaction, the chief financial officer now directly owns 13,063 shares of the company’s stock, valued at approximately $4,349,979. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO David M. Weber sold 300 shares of Abiomed stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $300.25, for a total transaction of $90,075.00. The disclosure for this sale can be found here. In the last three months, insiders sold 17,912 shares of company stock valued at $5,804,526. 3.00% of the stock is currently owned by insiders.

Shares of ABMD stock opened at $295.83 on Friday. The firm has a market cap of $13.46 billion, a P/E ratio of 102.36, a PEG ratio of 3.33 and a beta of 1.33. The company has a 50 day moving average of $309.35 and a 200-day moving average of $321.83. Abiomed, Inc. has a 12-month low of $261.27 and a 12-month high of $379.30.

Abiomed (NASDAQ:ABMDGet Rating) last announced its quarterly earnings data on Thursday, February 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.15. The business had revenue of $261.20 million during the quarter, compared to analyst estimates of $251.47 million. Abiomed had a return on equity of 15.19% and a net margin of 13.26%. Abiomed’s revenue was up 12.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.17 earnings per share. Equities research analysts anticipate that Abiomed, Inc. will post 4.36 earnings per share for the current fiscal year.

Abiomed Profile (Get Rating)

Abiomed, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Read More

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed, Inc. (NASDAQ:ABMDGet Rating).

Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.